| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Denmark | 29 | 2022 | 2654 | 1.40 | Why? |
| Heart Failure | 11 | 2021 | 6638 | 1.12 | Why? |
| Heart Failure, Systolic | 3 | 2017 | 39 | 1.01 | Why? |
| Anthracyclines | 1 | 2018 | 65 | 0.72 | Why? |
| Atrial Fibrillation | 5 | 2020 | 2320 | 0.72 | Why? |
| Myocardial Infarction | 5 | 2021 | 3361 | 0.70 | Why? |
| Receptors, N-Methyl-D-Aspartate | 1 | 2017 | 81 | 0.67 | Why? |
| Trastuzumab | 1 | 2018 | 108 | 0.67 | Why? |
| Fluorouracil | 1 | 2018 | 169 | 0.67 | Why? |
| Vasopressins | 1 | 2017 | 70 | 0.66 | Why? |
| Ventricular Function, Left | 5 | 2019 | 1555 | 0.66 | Why? |
| Aldosterone | 1 | 2017 | 155 | 0.63 | Why? |
| Registries | 13 | 2021 | 12327 | 0.62 | Why? |
| Stroke | 5 | 2021 | 8839 | 0.56 | Why? |
| Cardiotoxicity | 1 | 2018 | 365 | 0.55 | Why? |
| Testosterone Congeners | 3 | 2018 | 9 | 0.55 | Why? |
| Aspirin | 2 | 2018 | 1043 | 0.49 | Why? |
| Calcium | 1 | 2017 | 708 | 0.47 | Why? |
| Outpatients | 4 | 2017 | 3417 | 0.39 | Why? |
| Propensity Score | 1 | 2018 | 2690 | 0.38 | Why? |
| Brain Ischemia | 2 | 2021 | 2813 | 0.37 | Why? |
| Defibrillators, Implantable | 3 | 2019 | 624 | 0.35 | Why? |
| Incidence | 16 | 2021 | 25622 | 0.35 | Why? |
| Resistance Training | 4 | 2018 | 273 | 0.34 | Why? |
| Psychotic Disorders | 1 | 2017 | 924 | 0.33 | Why? |
| Heart Diseases | 3 | 2020 | 3503 | 0.33 | Why? |
| Androgens | 3 | 2018 | 267 | 0.32 | Why? |
| Renal Insufficiency, Chronic | 3 | 2021 | 2654 | 0.32 | Why? |
| Risk Assessment | 9 | 2021 | 25439 | 0.31 | Why? |
| Electric Countershock | 2 | 2019 | 284 | 0.31 | Why? |
| Hemorrhage | 1 | 2018 | 3013 | 0.29 | Why? |
| Thromboembolism | 1 | 2018 | 2101 | 0.28 | Why? |
| Ventricular Dysfunction, Left | 3 | 2019 | 993 | 0.28 | Why? |
| Neoplasms | 5 | 2019 | 17251 | 0.27 | Why? |
| Cardiovascular Diseases | 4 | 2022 | 11497 | 0.26 | Why? |
| Platelet Aggregation Inhibitors | 3 | 2019 | 1671 | 0.26 | Why? |
| Antineoplastic Agents | 2 | 2018 | 3550 | 0.25 | Why? |
| Follow-Up Studies | 11 | 2021 | 17020 | 0.24 | Why? |
| Survival Rate | 7 | 2018 | 9206 | 0.24 | Why? |
| Risk Factors | 19 | 2021 | 71621 | 0.22 | Why? |
| Anabolic Agents | 2 | 2018 | 49 | 0.21 | Why? |
| Stroke Volume | 3 | 2019 | 2153 | 0.20 | Why? |
| Natriuretic Peptide, Brain | 1 | 2007 | 1215 | 0.19 | Why? |
| Carpal Tunnel Syndrome | 1 | 2019 | 32 | 0.19 | Why? |
| Hospitalization | 9 | 2021 | 54280 | 0.19 | Why? |
| Epirubicin | 1 | 2018 | 21 | 0.19 | Why? |
| Middle Aged | 39 | 2021 | 270681 | 0.18 | Why? |
| Substance-Related Disorders | 3 | 2018 | 2038 | 0.18 | Why? |
| Mineralocorticoid Receptor Antagonists | 2 | 2019 | 203 | 0.18 | Why? |
| Aged, 80 and over | 19 | 2021 | 88759 | 0.18 | Why? |
| Ibuprofen | 1 | 2020 | 156 | 0.18 | Why? |
| Adrenergic beta-Antagonists | 2 | 2019 | 465 | 0.18 | Why? |
| Aged | 33 | 2021 | 215776 | 0.18 | Why? |
| Chitinase-3-Like Protein 1 | 1 | 2018 | 28 | 0.18 | Why? |
| Hyponatremia | 2 | 2013 | 371 | 0.18 | Why? |
| Coagulants | 1 | 2018 | 30 | 0.18 | Why? |
| Nursing Assessment | 1 | 2018 | 72 | 0.18 | Why? |
| Paraneoplastic Syndromes, Nervous System | 1 | 2017 | 4 | 0.18 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 1510 | 0.18 | Why? |
| Antibodies, Neoplasm | 1 | 2017 | 15 | 0.18 | Why? |
| Natriuretic Peptides | 1 | 2018 | 66 | 0.17 | Why? |
| Kidney Failure, Chronic | 3 | 2019 | 3222 | 0.17 | Why? |
| Diuretics | 1 | 2019 | 326 | 0.17 | Why? |
| Time Factors | 13 | 2020 | 31397 | 0.17 | Why? |
| Drug Users | 2 | 2018 | 234 | 0.17 | Why? |
| Male | 40 | 2021 | 367725 | 0.17 | Why? |
| Amyloidosis | 1 | 2019 | 178 | 0.17 | Why? |
| Cardiac Resynchronization Therapy | 1 | 2019 | 191 | 0.16 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2020 | 5277 | 0.16 | Why? |
| Adipokines | 1 | 2017 | 87 | 0.16 | Why? |
| Echocardiography | 3 | 2020 | 3661 | 0.16 | Why? |
| Quarantine | 2 | 2021 | 18418 | 0.16 | Why? |
| Hypertrophy, Left Ventricular | 1 | 2019 | 219 | 0.16 | Why? |
| Calcium-Binding Proteins | 1 | 2017 | 121 | 0.16 | Why? |
| Galectin 3 | 1 | 2017 | 76 | 0.16 | Why? |
| Female | 37 | 2021 | 380317 | 0.16 | Why? |
| Ischemic Attack, Transient | 1 | 2020 | 439 | 0.15 | Why? |
| Peptide Fragments | 1 | 2007 | 2075 | 0.15 | Why? |
| Myocardial Contraction | 1 | 2017 | 123 | 0.15 | Why? |
| Automobile Driving | 1 | 2018 | 222 | 0.15 | Why? |
| Hypogonadism | 1 | 2016 | 196 | 0.14 | Why? |
| Arrhythmias, Cardiac | 2 | 2019 | 2510 | 0.14 | Why? |
| Acute Coronary Syndrome | 2 | 2020 | 2107 | 0.14 | Why? |
| Cohort Studies | 8 | 2022 | 36005 | 0.14 | Why? |
| Magnesium | 1 | 2017 | 290 | 0.14 | Why? |
| Humans | 54 | 2022 | 930598 | 0.14 | Why? |
| Vascular Stiffness | 1 | 2018 | 264 | 0.14 | Why? |
| Lithium | 2 | 1988 | 56 | 0.14 | Why? |
| Digestive System Diseases | 1 | 2019 | 378 | 0.14 | Why? |
| Educational Status | 1 | 2021 | 1451 | 0.14 | Why? |
| Glomerular Filtration Rate | 2 | 2017 | 1262 | 0.14 | Why? |
| Testosterone | 2 | 2017 | 596 | 0.13 | Why? |
| Secondary Prevention | 1 | 2019 | 762 | 0.13 | Why? |
| Death, Sudden, Cardiac | 1 | 2019 | 522 | 0.13 | Why? |
| Hematologic Tests | 1 | 2017 | 521 | 0.12 | Why? |
| Vascular Calcification | 1 | 2017 | 396 | 0.12 | Why? |
| Patient Reported Outcome Measures | 1 | 2018 | 912 | 0.12 | Why? |
| Dose-Response Relationship, Drug | 4 | 2018 | 3776 | 0.12 | Why? |
| Prognosis | 8 | 2020 | 32490 | 0.12 | Why? |
| Myocardial Ischemia | 1 | 2019 | 781 | 0.12 | Why? |
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2012 | 49 | 0.12 | Why? |
| Cardiovascular Agents | 1 | 2018 | 663 | 0.12 | Why? |
| Steroids | 1 | 2018 | 904 | 0.12 | Why? |
| Renal Insufficiency | 1 | 2019 | 810 | 0.12 | Why? |
| Primary Prevention | 1 | 2019 | 778 | 0.11 | Why? |
| Adipose Tissue | 1 | 2017 | 612 | 0.11 | Why? |
| Pulmonary Disease, Chronic Obstructive | 3 | 2021 | 3832 | 0.11 | Why? |
| Insulin Resistance | 1 | 2017 | 669 | 0.11 | Why? |
| Renal Dialysis | 2 | 2019 | 4358 | 0.11 | Why? |
| Cerebrovascular Disorders | 1 | 2019 | 1040 | 0.11 | Why? |
| Respiratory Tract Diseases | 1 | 2019 | 1061 | 0.11 | Why? |
| Bipolar Disorder | 3 | 2021 | 744 | 0.11 | Why? |
| Antibodies | 1 | 2017 | 846 | 0.11 | Why? |
| Troponin T | 1 | 2016 | 771 | 0.11 | Why? |
| Breast Neoplasms | 2 | 2019 | 3633 | 0.10 | Why? |
| Glycopeptides | 1 | 2012 | 199 | 0.10 | Why? |
| Patient Readmission | 1 | 2019 | 1543 | 0.10 | Why? |
| Biomarkers | 6 | 2018 | 23361 | 0.10 | Why? |
| Heart Ventricles | 1 | 2018 | 1139 | 0.10 | Why? |
| Adult | 20 | 2021 | 244371 | 0.09 | Why? |
| Terminal Care | 1 | 2019 | 928 | 0.09 | Why? |
| Athletes | 1 | 2016 | 1047 | 0.09 | Why? |
| Case-Control Studies | 7 | 2021 | 17671 | 0.09 | Why? |
| Troponin I | 1 | 2016 | 1298 | 0.09 | Why? |
| Retrospective Studies | 11 | 2021 | 105322 | 0.08 | Why? |
| Comorbidity | 6 | 2021 | 34796 | 0.08 | Why? |
| Proportional Hazards Models | 4 | 2020 | 6543 | 0.08 | Why? |
| Monitoring, Physiologic | 1 | 2018 | 1956 | 0.08 | Why? |
| Blood Pressure | 1 | 2018 | 2198 | 0.08 | Why? |
| Mortality | 2 | 2020 | 7132 | 0.08 | Why? |
| Mental Disorders | 2 | 2021 | 6742 | 0.08 | Why? |
| Vital Capacity | 2 | 2017 | 399 | 0.07 | Why? |
| Indoles | 1 | 2013 | 1243 | 0.07 | Why? |
| Kidney | 1 | 2019 | 3648 | 0.07 | Why? |
| Myocardium | 1 | 2017 | 2323 | 0.07 | Why? |
| Wounds and Injuries | 1 | 2017 | 1708 | 0.07 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.07 | Why? |
| Communicable Disease Control | 4 | 2022 | 29620 | 0.07 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.07 | Why? |
| Forced Expiratory Volume | 2 | 2017 | 632 | 0.07 | Why? |
| Young Adult | 10 | 2020 | 93724 | 0.07 | Why? |
| Spirometry | 2 | 2017 | 524 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.07 | Why? |
| Cause of Death | 1 | 2018 | 4823 | 0.07 | Why? |
| Diphosphonates | 1 | 2004 | 121 | 0.06 | Why? |
| Electrocardiography | 1 | 2018 | 3957 | 0.06 | Why? |
| Prospective Studies | 6 | 2020 | 43301 | 0.06 | Why? |
| Adolescent | 9 | 2020 | 86841 | 0.06 | Why? |
| Forecasting | 1 | 2018 | 4492 | 0.06 | Why? |
| Predictive Value of Tests | 4 | 2020 | 9537 | 0.06 | Why? |
| Blood Glucose | 1 | 2017 | 3642 | 0.06 | Why? |
| Coronary Artery Disease | 1 | 2017 | 2570 | 0.06 | Why? |
| Triage | 2 | 2018 | 7151 | 0.06 | Why? |
| Confidence Intervals | 2 | 2020 | 744 | 0.06 | Why? |
| Treatment Outcome | 6 | 2019 | 51732 | 0.06 | Why? |
| Disease Progression | 2 | 2017 | 13580 | 0.06 | Why? |
| Pulmonary Embolism | 1 | 2021 | 4775 | 0.06 | Why? |
| Linear Models | 2 | 2018 | 1914 | 0.05 | Why? |
| Quality of Life | 3 | 2018 | 9820 | 0.05 | Why? |
| Bone Neoplasms | 1 | 2004 | 287 | 0.05 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.05 | Why? |
| Hypertension | 2 | 2020 | 8895 | 0.05 | Why? |
| Echocardiography, Doppler, Pulsed | 1 | 2019 | 40 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Poisson Distribution | 1 | 2020 | 348 | 0.05 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.05 | Why? |
| Factor VII | 1 | 2018 | 6 | 0.05 | Why? |
| Factor X | 1 | 2018 | 18 | 0.05 | Why? |
| Diastole | 1 | 2019 | 168 | 0.05 | Why? |
| Echocardiography, Doppler, Color | 1 | 2019 | 114 | 0.05 | Why? |
| Diabetes Mellitus | 2 | 2021 | 8207 | 0.05 | Why? |
| Imidazoles | 1 | 2004 | 631 | 0.05 | Why? |
| Lung | 2 | 2017 | 31049 | 0.04 | Why? |
| Logistic Models | 3 | 2017 | 9089 | 0.04 | Why? |
| Adrenergic beta-1 Receptor Agonists | 1 | 2017 | 6 | 0.04 | Why? |
| Patient Compliance | 1 | 1988 | 1468 | 0.04 | Why? |
| Prothrombin | 1 | 2018 | 149 | 0.04 | Why? |
| Protein S | 1 | 2018 | 150 | 0.04 | Why? |
| Dobutamine | 1 | 2017 | 36 | 0.04 | Why? |
| Systole | 1 | 2018 | 252 | 0.04 | Why? |
| Inhibins | 1 | 2016 | 4 | 0.04 | Why? |
| Protein C | 1 | 2018 | 141 | 0.04 | Why? |
| Gonadotropins | 1 | 2016 | 21 | 0.04 | Why? |
| Antibiotics, Antineoplastic | 1 | 2018 | 128 | 0.04 | Why? |
| Libido | 1 | 2016 | 32 | 0.04 | Why? |
| Follicle Stimulating Hormone | 1 | 2016 | 73 | 0.04 | Why? |
| Mood Disorders | 1 | 2021 | 431 | 0.04 | Why? |
| Luteinizing Hormone | 1 | 2016 | 91 | 0.04 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.04 | Why? |
| Anti-Mullerian Hormone | 1 | 2016 | 35 | 0.04 | Why? |
| Echocardiography, Stress | 1 | 2017 | 65 | 0.04 | Why? |
| Lipoproteins | 1 | 2018 | 240 | 0.04 | Why? |
| Anticoagulants | 1 | 2018 | 9563 | 0.04 | Why? |
| Pulse Wave Analysis | 1 | 2017 | 221 | 0.04 | Why? |
| Prevalence | 4 | 2020 | 25773 | 0.04 | Why? |
| Galectins | 1 | 2017 | 109 | 0.04 | Why? |
| Emergency Service, Hospital | 2 | 2018 | 14232 | 0.04 | Why? |
| Glucose Tolerance Test | 1 | 2017 | 238 | 0.04 | Why? |
| Multivariate Analysis | 2 | 2017 | 5440 | 0.04 | Why? |
| Ventricular Remodeling | 1 | 2019 | 349 | 0.04 | Why? |
| Thrombin | 1 | 2018 | 325 | 0.04 | Why? |
| Intra-Abdominal Fat | 1 | 2017 | 227 | 0.03 | Why? |
| Erectile Dysfunction | 1 | 2016 | 141 | 0.03 | Why? |
| Schizophrenia | 2 | 2021 | 1018 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.03 | Why? |
| Bone Density | 1 | 2017 | 335 | 0.03 | Why? |
| Double-Blind Method | 2 | 2017 | 5988 | 0.03 | Why? |
| Blood Pressure Determination | 1 | 2018 | 450 | 0.03 | Why? |
| Magnetic Resonance Imaging, Cine | 1 | 2018 | 669 | 0.03 | Why? |
| Norway | 1 | 2017 | 1004 | 0.03 | Why? |
| Sex Distribution | 1 | 2020 | 2083 | 0.03 | Why? |
| Fibrosis | 1 | 2017 | 800 | 0.03 | Why? |
| Blood Proteins | 1 | 2017 | 551 | 0.03 | Why? |
| Cross-Sectional Studies | 5 | 2018 | 53120 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2018 | 1654 | 0.03 | Why? |
| Blood Coagulation Tests | 1 | 2018 | 855 | 0.03 | Why? |
| Chronic Disease | 1 | 2007 | 5139 | 0.03 | Why? |
| Drug Prescriptions | 1 | 2020 | 1062 | 0.03 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.03 | Why? |
| Netherlands | 1 | 2020 | 3533 | 0.03 | Why? |
| Patient Satisfaction | 1 | 2004 | 2517 | 0.03 | Why? |
| Hypotension | 1 | 2013 | 392 | 0.03 | Why? |
| Activities of Daily Living | 1 | 2018 | 1530 | 0.02 | Why? |
| Drug Administration Schedule | 2 | 2004 | 2324 | 0.02 | Why? |
| Up-Regulation | 1 | 2017 | 2249 | 0.02 | Why? |
| Patient Education as Topic | 1 | 2018 | 1476 | 0.02 | Why? |
| Glycated Hemoglobin A | 1 | 2017 | 1316 | 0.02 | Why? |
| In Vitro Techniques | 1 | 2012 | 1027 | 0.02 | Why? |
| Protein Precursors | 1 | 2012 | 425 | 0.02 | Why? |
| Antihypertensive Agents | 1 | 2020 | 1962 | 0.02 | Why? |
| Acute Disease | 1 | 2020 | 6029 | 0.02 | Why? |
| Employment | 1 | 2018 | 1754 | 0.02 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.02 | Why? |
| Morbidity | 1 | 2012 | 1426 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Fatigue | 1 | 2016 | 2479 | 0.02 | Why? |
| Hospitals, University | 1 | 2017 | 4173 | 0.02 | Why? |
| Blood Coagulation | 1 | 2018 | 2768 | 0.02 | Why? |
| Self Report | 1 | 2017 | 3802 | 0.02 | Why? |
| Clinical Competence | 1 | 2018 | 3263 | 0.02 | Why? |
| Metyrapone | 1 | 1963 | 36 | 0.02 | Why? |
| Smoking | 1 | 2017 | 3358 | 0.02 | Why? |
| Adrenocorticotropic Hormone | 1 | 1963 | 107 | 0.02 | Why? |
| Pituitary Gland | 1 | 1963 | 65 | 0.02 | Why? |
| Toxicology | 1 | 1963 | 52 | 0.02 | Why? |
| Asthma | 1 | 2021 | 4383 | 0.01 | Why? |
| Chlorpromazine | 1 | 1963 | 130 | 0.01 | Why? |
| Child | 2 | 2021 | 70012 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.01 | Why? |
| Infusions, Intravenous | 1 | 2004 | 1224 | 0.01 | Why? |
| Infant, Newborn | 1 | 2020 | 23105 | 0.01 | Why? |
| Combined Modality Therapy | 1 | 1988 | 3395 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.01 | Why? |
| Age Factors | 1 | 2019 | 21039 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Thrombosis | 1 | 2018 | 7504 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2021 | 15909 | 0.01 | Why? |
| Depression | 1 | 2016 | 14116 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Recurrence | 1 | 1981 | 3675 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.01 | Why? |
| Animals | 1 | 1988 | 78931 | 0.00 | Why? |
| Surveys and Questionnaires | 1 | 2004 | 43792 | 0.00 | Why? |